Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 20, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 47,244 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on January 18, 2006, and the Company was advised of it on January 19, 2006.
Outlook, Risks, and Management Commentary
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—are interested in the shares held in the GSK Trust in the same capacity as other employees. No guidance, outlook, or specific risk factors regarding the company's operations are provided in this text.
Investor Verification Points
- Verify the impact of the 47,244 share transfer on the total outstanding share count.
- Confirm the specific allocation of shares among participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full terms of the GSK Trust to understand the discretionary nature of the holdings.
- Check subsequent filings for any additional director transactions related to the GSK Trust.